Welcome to the TLDR Biotech newsletter!

Our aim is to be your one-stop source for biotech and pharma updates - all with one daily email.

We’ll likely tweak the exact format and delivery over the next few weeks as we get our feet under us.

So if you have any feedback on what you like (or don’t), we’d love to hear from you!

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

THE GOOD
Approvals

bluebird bio’s sickle cell gene therapy gets commercial debut
Cell & gene therapy, sickle cell - Read more

Pfizer’s sickle cell therapy gets NHS go-ahead after price cut
Small molecule, sickle cell, NHS - Read more

MHRA approves cabotegravir formulations
Small molecule, antiviral, HIV/AIDS - Read more

THE GOOD
Clinical Trials

Apple (the iPhone one) Watch gets FDA Medical Device Development Tools designation
Medical device, atrial fibrillation - Read more

ADC Therapeutics shows off positive Phase 2 data, announces $105M stock sale
ADC, cancer, lymphoma - Read more

THE GOOD
Company Launch

OverT Bio launches with $16M and ambitious cancer goals
Cell therapy, solid tumors, cancer - Read more

THE GOOD
Fundraises

MRC Center for Medical Mycology (University of Exeter) £3.4 million to combat antifungal drug resistance - Read more

Allegria Therapeutics - $3.5M Seed Funding
Mast cells - Read more

THE GOOD
Mergers & Acquisitions, Business Development

Sentynl Therapeutics buys worldwide rights to commercial asset from Eiger BioPharmaceuticals
Small molecule, progeria - Read more

Mithra begins exclusive negotiations with Gedeon Richter
Monetization process, women’s health - Read more

THE GOOD
Partnerships

Chiesi partners with Gossamer Bio (recipient)
$160M development reimbursements - additional $146M regulatory and $180M sales milestones
Small molecule, pulmonary arterial hypertension - Read more

AstraZeneca ups investment in Cellectis, 44% share ownership
CAR-T, cell therapy, cancer - Read more

Novo Nordisk Foundation partners with Bill & Melinda Gates Foundation
Infectious disease, antimicrobial resistance, vaccines - Read more

THE GOOD
Politics & Policy

Canadian city commits to $10M women’s health investment - Read more 

THE GOOD
Regulatory

FDA REMS (risk evaluation and mitigation strategy) logic model gets new draft guidance - Read more

THE GOOD
Research

No secondary cancers due to CAR-T; analysis - Read more

THE GOOD
Strategic Plans

PharmAla launches MDMA/MDXX prescriber portal
Small molecule, psychedelics, PTSD - Read more

Eccogene (AstraZeneca-partnered) plots 2025 Nasdaq IPO
GLP-1, NASH - Read more

Neurocrine wants to drive awareness, diagnosis for approved med
Small molecule, tardive dyskinesia - Read more

BioNTech wants 10 approved indications by 2030
mRNA, antibody, small molecule - Read more 

GOOD OR BAD?
Medicare

Centers for Medicare & Medicaid Services want negotiation changes for next round
Inflation Reduction Act - Read more

THE BAD
Clinical Trials

GlycoMimetics stock shattered after Phase 3 miss
Small molecule, cancer, leukemia - Read more

EyePoint Pharmaceuticals Phase 2 endpoint fails to delivery
Small molecule, medical insert, retinopathy - Read more

THE UGLY
Lawsuits

Amneal Pharmaceuticals Opioid settlement, $270M - Read more

THE UGLY
Politics & Policy

US lawmaker demands H5N1 avian flu transparency - Read more

THE UGLY
Warning Letters, Form 483s

Zydus Lifescience goes for 2nd 483 in one month - Read more

You’re all caught up on the latest Pharma & Biotech News!

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍